BI-1361849 is a mRNA Vaccine owned by Boehringer Ingelheim International, and is involved in 1 clinical trial, which was completed.
BI-1361849 (CV-9202) is a mRNA-derived lung cancer therapeutic that containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, BI-1361849 stimulates the immune system to mount both humoral and cellular responses against NSCLC cells.
The revenue for BI-1361849 is expected to reach a total of $373m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BI-1361849 NPV Report.
BI-1361849 (CV-9202) is under development for the treatment of non-small cell lung cancer in combination with radiation therapy and afatinib. It is administered intradermally. It is a RNActive-derived mRNA (messengerRNA) therapeutic comprising of six RNActive-derived molecules coding for 6 different NSCLC associated antigens, MAGE-C1, MAGE-C2, NY-ESO-1, survivin, 5T4 and Muc1. It is developed based on the RNActive technology. It was under development for the treatment of non-small cell lung cancer as a first line therapy.
Curevac is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger rna molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its product pipeline includes Cv0501, Cv2cov, Flu Sv Mrna and Cvsqiv. Curevac mrna-based prophylactic vaccines candidates comprise cv7202 and cv8102. it also carries out the research and development. The company Cv8102, a lead oncology candidate is designed to modulate the tumor microenvironment. Its products are used in the treatment of prostate cancer and non-small cell lung cancer, and infectious diseases such as rabies, rotavirus, influenza, and other undisclosed. Curevac is headquartered in Tubingen, Baden-Wurttemberg, Germany.
The company reported revenues of (Euro) EUR103 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of EUR48.9 million in FY2020. The operating loss of the company was EUR412.3 million in FY2021, compared to an operating loss of EUR109.8 million in FY2020. The net loss of the company was EUR411.7 million in FY2021, compared to a net loss of EUR129.1 million in FY2020. The company reported revenues of EUR11.2 million for the third quarter ended September 2022, a decrease of 44.3% over the previous quarter.
Quick View – BI-1361849
|Highest Development Stage|